Drug adherence, glycemic control, and weight reduction with subcutaneous semaglutide in real-world management of type 2 diabetes
Authors' conclusion
Long-term real-world adherence with semaglutide was relatively stable. Semaglutide use was associated with sustained glycemic control and weight reduction in patients with T2D and relatively good baseline glycemic control, especially among those with high adherence, supporting its use for long-term management of T2D.
Study context
- Population
- Adults with T2D at Maccabi Healthcare Services, Israel, initiating subcutaneous semaglutide (August 2019 - June 2022); mean age 62.2 years, HbA1c 7.6 %, BMI 33.7 kg/m²11,513 women
- Participants
- 23,442 adults
- Outcome
- Absolute change in HbA1c and relative change in body-weight from baseline; adherence (PDC)
- Follow-up
- Up to 3 years
Methodological detailsreal-world
- Real-world
Main finding
As reported in the abstract
- Mean HbA1c reduction at 6 months (%-points)
- 0.77 [95 %CI 0.75-0.78]
- Mean HbA1c reduction at 2 years (%-points)
- 0.57 [0.53-0.61]
- Mean HbA1c reduction at 3 years (%-points)
- 0.35 [0.27-0.44]
- Body-weight reduction at 6 months
- 4.9 % [4.8-5.0]
- Body-weight reduction at 2 years
- 5.3% [5.1-5.5]
- Body-weight reduction at 3 years
- 4.5 % [3.7-5.2]
Observational data: associations, not effects.
Further findings
Adherence (median Proportion of Days Covered (PDC)) among patients with ≥2 years of potential follow-up
- Patients with ≥2 years of potential follow-up
- 6049
- Median PDC 0-6 months
- 83.9 %
- Median PDC 18-24 months
- 74.6 %
- Higher PDC associated with more pronounced HbA1c and body-weight reductions
Original publication
Drug adherence, glycemic control, and weight reduction with subcutaneous semaglutide in real-world management of type 2 diabetes. Diabetes Res Clin Pract. Published 8 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →